Intellia Therapeutics (NTLA) Revenue (2015 - 2026)
Intellia Therapeutics (NTLA) reported Revenue of $15.0 million for Q1 2026, down 9.5% year-over-year from $16.6 million in Q1 2025, and down 34.62% on a QoQ basis from $23.0 million in Q4 2025.
Intellia Therapeutics (NTLA) has 12 years of Revenue data on file, last reported at $15.0 million in Q1 2026.
- Quarterly Revenue fell 9.5% year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.1 million (up 45.04% YoY) and the FY2025 annual result came in at $67.7 million, up 16.92% from the prior year.
- Revenue fell to $15.0 million in Q1 2026 per NTLA's latest filing, from $23.0 million in the prior quarter.
- Across five years, Revenue topped out at $28.9 million in Q1 2024 and bottomed at -$1.9 million in Q4 2023.
- The 5-year median for Revenue is $13.6 million (2022), against an average of $13.5 million.
- The widest annual swing landed in 2022, when Revenue soared 4322.0%; it then slumped 114.12% in 2023.
- Tracing NTLA's Revenue over 5 years: stood at $13.6 million in 2022, then tumbled by 114.12% to -$1.9 million in 2023, then soared by 771.57% to $12.9 million in 2024, then surged by 78.79% to $23.0 million in 2025, then plunged by 34.62% to $15.0 million in 2026.
- Per Business Quant, the three latest NTLA Revenue figures stand at $15.0 million (Q1 2026), $23.0 million (Q4 2025), and $13.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | 15.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.05 Mn |
| Dec 31, 2025 | 23.02 Mn |
| Sep 30, 2025 | 13.78 Mn |
| Jun 30, 2025 | 14.25 Mn |
| Mar 31, 2025 | 16.63 Mn |
| Dec 31, 2024 | 12.87 Mn |
| Sep 30, 2024 | 9.11 Mn |
| Jun 30, 2024 | 6.96 Mn |
| Mar 31, 2024 | 28.94 Mn |
| Dec 31, 2023 | -1.92 Mn |
| Sep 30, 2023 | 11.99 Mn |
| Jun 30, 2023 | 13.59 Mn |
| Mar 31, 2023 | 12.61 Mn |
| Dec 31, 2022 | 13.57 Mn |
| Sep 30, 2022 | 13.27 Mn |
| Jun 30, 2022 | 14.03 Mn |
| Mar 31, 2022 | 11.25 Mn |
| Dec 31, 2021 | 12.85 Mn |
| Sep 30, 2021 | 300,000.00 |
| Jun 30, 2021 | 6.55 Mn |
| Mar 31, 2021 | 6.45 Mn |
| Dec 31, 2020 | 6.60 Mn |
| Sep 30, 2020 | 22.22 Mn |
| Jun 30, 2020 | 16.26 Mn |
| Mar 31, 2020 | 5.00 Mn |
| Dec 31, 2019 | 10.94 Mn |
| Sep 30, 2019 | 10.62 Mn |
| Jun 30, 2019 | 11.12 Mn |
| Mar 31, 2019 | 10.43 Mn |
| Dec 31, 2018 | 7.88 Mn |
| Sep 30, 2018 | 7.41 Mn |
| Jun 30, 2018 | 7.68 Mn |
| Mar 31, 2018 | 7.47 Mn |
| Dec 31, 2017 | 6.67 Mn |
| Sep 30, 2017 | 7.32 Mn |
| Jun 30, 2017 | 5.92 Mn |
| Mar 31, 2017 | 6.22 Mn |
| Dec 31, 2016 | 5.63 Mn |
| Sep 30, 2016 | 4.87 Mn |
| Jun 30, 2016 | 4.21 Mn |
| Mar 31, 2016 | 1.78 Mn |
| Dec 31, 2015 | 1.69 Mn |
| Sep 30, 2015 | 1.69 Mn |
| Jun 30, 2015 | 1.38 Mn |
| Mar 31, 2015 | 1.29 Mn |